Gyre Therapeutics Appoints New CMO, Elects Director
Ticker: GYRE · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Aug 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-compensation
TL;DR
Gyre Therapeutics brings in a new CMO and adds a director to the board.
AI Summary
Gyre Therapeutics, Inc. announced on August 6, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Drachman.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts or a focus on specific therapeutic areas for Gyre Therapeutics.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate strategic shifts or challenges within the company, impacting its future direction and performance.
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan G. Drachman (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- August 6, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Gyre Therapeutics?
Dr. Jonathan G. Drachman has been appointed as the new Chief Medical Officer.
Who was elected to the Board of Directors of Gyre Therapeutics?
Ms. Sarah E. Kelly was elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 6, 2024.
What is the principal executive office address for Gyre Therapeutics?
The principal executive office is located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What former companies were Gyre Therapeutics previously known as?
Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Filing Stats: 1,018 words · 4 min read · ~3 pages · Grade level 10 · Accepted 2024-08-08 16:14:43
Filing Documents
- ef20033805_8k.htm (8-K) — 36KB
- ef20033805_ex99-1.htm (EX-99.1) — 10KB
- image0.jpg (GRAPHIC) — 40KB
- 0001140361-24-036404.txt ( ) — 241KB
- gyre-20240806.xsd (EX-101.SCH) — 4KB
- gyre-20240806_lab.xml (EX-101.LAB) — 21KB
- gyre-20240806_pre.xml (EX-101.PRE) — 16KB
- ef20033805_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated August 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: August 8, 2024 By: /s/ Ruoyu Chen Name: Ruoyu Chen Title: Chief Financial Officer